COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,822 Articles (22,968 medRxiv, 8,854 bioRxiv)

Most recent first Previous |  Page 1999: Articles 19981-19990  | Next

Oral clarithromycin in COVID-19 of moderate severity: the ACHIEVE open-label trial using concurrent matched comparators
Tsiakos, K., Tsakiris, A., Tsibris, G., Voutsinas, P., Panagopoulos, P., Kosmidou, M., Petrakis, V., Gravvani, A., Gkavogianni, T., Klouras, E., Katrini, K., Koufargyris, P., Rapti, I., Karageorgos, A., Vrentzos, E., Damoulari, C., Zarkada, V., Sidiropoulou, C., Artemi, S., Papapostolou, A., Michelakis, E., Georgiopoulou, M., Myrodia, D.-M., Tsiamalos, P., Syrigos, K., Chrysos, G., Nitsotolis, T., Milionis, H., Poulakou, G., Giamarellos-Bourboulis, E.
10.1101/2020.12.22.20248753 — Posted: 2020-12-26
Does COVID-19 Testing Create More Cases? An Empirical Evidence on the Importance of Mass Testing During a Pandemic
Ahmed, A.
10.1101/2020.12.23.20248740 — Posted: 2020-12-26
MHC Haplotyping of SARS-CoV-2 patients: HLA subtypes are not associated with the presence and severity of Covid-19 in the Israeli population
Ben-shachar, s., Barda, N., Manor, S. S., Israeli, S., Dagan, N., Carmi, S., Balicer, R., Zisser, B., Louzoun, Y.
10.1101/2020.12.23.20248148 — Posted: 2020-12-26
Seropositivity in blood donors and pregnant women during 9-months of SARS-CoV-2 transmission in Stockholm, Sweden
C Dopico, X., Muschiol, S., Christian, M., Hanke, L., Sheward, D. J., Grinberg, N. F., Bogdanovic, G., Mcinerney, G., Allander, T., Wallace, C., Murrell, B., Albert, J., Karlsson Hedestam, G. B.
10.1101/2020.12.24.20248821 — Posted: 2020-12-26
Changes in inflammatory and immune drivers in response to immunomodulatory therapies in COVID-19
Wang, S. Y., Chang, C.-H., Meizlish, M., Bahel, P., Rinder, H., Lee, A. I., Chun, H.
10.1101/2020.12.23.20248547 — Posted: 2020-12-26
Mechanical ventilation affects respiratory microbiome of COVID-19 patients and its interactions with the host
Llorens-Rico, V., Gregory, A. C., Van Weyenbergh, J., Jansen, S., Van Buyten, T., Qian, J., Braz, M., Menezes, S. M., Van Mol, P., Vanderbeke, L., Dooms, C., Gunst, J., Hermans, G., Meersseman, P., CONTAGIOUS collaborators, , Wauters, E., Neyts, J., Lambrechts, D., Wauters, J., Raes, J.
10.1101/2020.12.23.20248425 — Posted: 2020-12-26 Discussion: Onsite | Offsite
Characteristics of SARS-CoV-2 Testing for Rapid Diagnosis of COVID-19 during the Initial Stages of a Global Pandemic
Guthrie, J. L., Chen, A. J., Budhram, D. R., Cronin, K., Peci, A., Nelson, P., Mallo, G. V., Broukhanski, G., Murti, M., Majury, A., Mazzulli, T., Allen, V. G., Patel, S. N., Kus, J. V., Tran, V., Gubbay, J. B.
10.1101/2020.12.23.20231589 — Posted: 2020-12-26
Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil
Voloch, C. M., Francisco Junior, R. d. S., de Almeida, L. G. P., Cardoso, C. C., Brustolini, O. J., Gerber, A. L., Guimaraes, A. P. d. C., Mariani, D., da Costa, R. M., Ferreira Junior, O. C., Covid19-UFRJ Workgroup, , LNCC-Workgroup, , Cavalcanti, A. C., Frauches, T. S., de Mello, C. M. B., Galiez, R. d. M., Faffe, D. S., Castineira, T. M. P. P., TANURI, A., de Vasconcelos, A. T. R.
10.1101/2020.12.23.20248598 — Posted: 2020-12-26
Potent in vitro anti-SARS-CoV-2 activity by gallinamide A and analogues via inhibition of cathepsin L
Ashhurst, A., Tang, A., Fajtova, P., Yoon, M., Aggarwal, A., Stoye, A., Larance, M., Beretta, L., Drelich, A., Skinner, D., Li, L., Meek, T., McKerrow, J., Hook, V., Tseng, C.-T., Turville, S. G., Gerwick, W., O'Donoghue, A., Payne, R. J.
10.1101/2020.12.23.424111 — Posted: 2020-12-25
A SARS-CoV-2 spike binding DNA aptamer that inhibits pseudovirus infection in vitro by an RBD independent mechanism
Schmitz, A., Weber, A., Bayin, M., Breuers, S., Famulok, M., Mayer, G.
10.1101/2020.12.23.424171 — Posted: 2020-12-25

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).